You are here

Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Istituto di Ematologia
Roma, Lazio, 00161 Italy
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male adults (aged 18 to 65 years) with Haemophilia A (all severity levels) who
currently use FVIII treatment either prophylactically or on-demand using traditional
factor VIII delivery mechanisms.

- Patients advised for any reason by their physician to switch to a new factor VIII
delivery device, namely FuseNGO, before receiving any details about this study or
Patients who requested to be treated with a new factor VIII delivery device namely
FuseNGO, before receiving any details about this study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients not previously recommended by their physician to switch to this new factor
VIII delivery system or Patients who did not previously ask their physician to be
switched to this new factor VIII delivery system.

- Patients for which it is anticipated that 10 infusions will not occur in the 12 months
following their inclusion in the study.

NCT01959919
Pfizer
Completed
Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Healthy Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Her2(-) Breast Cancer ER/PR(+)
NCT02924584
All Genders
0+
Years
Tainan City,
Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo
This study aims to investigate prospectively throughout a period of 3- 6 months and not to exceed 12 months (according to local therapeutic plans) patients experiences of treatment with Factor VIII in the new device named FuseNGO, a new delivery system for Factor VIII compared to their previous delivery system.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Approximately 200 patients with Hemophilia A (all severity levels) will be enrolled in approximately 20 centers in Italy.
Hemophilia A
Device: Refacto FusENGO
Dosage will be chosen by PI based on patient condition.
Arm 1: Device
Intervention: Device: Refacto FusENGO
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
87
December 2016
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male adults (aged 18 to 65 years) with Haemophilia A (all severity levels) who currently use FVIII treatment either prophylactically or on-demand using traditional factor VIII delivery mechanisms.
  • Patients advised for any reason by their physician to switch to a new factor VIII delivery device, namely FuseNGO, before receiving any details about this study or Patients who requested to be treated with a new factor VIII delivery device namely FuseNGO, before receiving any details about this study.

Exclusion Criteria:

  • Patients not previously recommended by their physician to switch to this new factor VIII delivery system or Patients who did not previously ask their physician to be switched to this new factor VIII delivery system.
  • Patients for which it is anticipated that 10 infusions will not occur in the 12 months following their inclusion in the study.
Sexes Eligible for Study: Male
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01959919
B1831081
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now